GlassScriptPhysician profile
Lisa Rothman
NPI 1831538644
$7,264.46
in general payments reported to CMS, 2019-2025
26 companies · $1,681 in 2025
The $1,681 reported for 2025 was more than what a typical Procedural Dermatology provider received nationally (typical 2025 total: $599).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $39.89 · 2020: $36.59 · 2021: $548 · 2022: $1,106 · 2023: $2,211 · 2024: $1,642 · 2025: $1,681.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,249 · Education: $285.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,249.08 |
| Education | $285.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $888.77 | 2022-2025 | Tremfya |
| Galderma Laboratories, L.P. | $542.93 | 2021-2025 | Aklief, Nemluvio, Oracea |
| Abbvie INC. | $536.50 | 2019-2025 | Rinvoq |
| Lilly USA, LLC | $496.00 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Sun Pharmaceutical Industries INC. | $468.33 | 2021-2025 | Winlevi, Absorica Ld, Ilumya |
| Genzyme Corporation | $453.97 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $445.01 | 2021-2025 | |
| Leo Pharma INC. | $404.14 | 2021-2025 | Adbry, Anzupgo |
| Dermavant Sciences, INC. | $396.62 | 2023-2024 | Vtama |
| Amgen INC. | $372.63 | 2021-2025 | Otezla, Otezla |
| Arcutis Biotherapeutics, INC. | $309.76 | 2023-2025 | Zoryve |
| Incyte Corporation | $308.56 | 2024-2025 | Opzelura |
| E.R. Squibb & Sons, L.L.C. | $274.14 | 2022-2025 | Sotyktu |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $246.74 | 2021-2024 | Cabtreo, Jublia, Arazlo |
| Regeneron Healthcare Solutions, INC. | $201.03 | 2021-2025 | Dupixent, Libtayo |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $188.30 | 2021-2025 | |
| Mayne Pharma Commercial LLC | $180.82 | 2021-2025 | |
| Almirall LLC | $144.95 | 2022 | |
| Ucb, INC. | $132.08 | 2021-2025 | Bimzelx |
| Biofrontera INC. | $84.70 | 2021-2023 | Ameluz, Xepi, Bf-Rhodoled |
| Verrica Pharmaceuticals INC. | $44.86 | 2023-2024 | Ycanth |
| Genentech USA, INC. | $38.64 | 2021-2022 | |
| Epi Health, LLC | $38.05 | 2021-2022 | |
| Helsinn Therapeutics (U.S.), INC. | $30.99 | 2022-2023 | Valchlor |
| Lnhc, INC | $21.38 | 2025 | Zelsuvmi |
| Kyowa Kirin, INC. | $14.56 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Rothman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.